Carlsmed Reports the US FDA’s Approval of aprevo Cervical Breakthrough Fusion Device
Shots:
- The US FDA has granted FDA 510(k) clearance to aprevo Cervical ACDF Interbody System, with its launch planned in 2025 across the US, expanding its portfolio of personalized spine surgery
- Previously reported data showed improvement in spinal alignment by reducing PI-LL mismatch compared to traditional spine surgery. Optimal alignment during spine fusion surgery is linked to fewer complications
- Aprevo devices use Carlsmed’s AI-driven platform to create personalized spine fusion implants, delivered in under two weeks
Ref: Businesswire | Image: Carlsmed
Related News:- BrioHealth Solutions Initiates Patient Recruitment in INNOVATE Trial of BrioVAD System for Advanced Heart Failure
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
